Investment in the company’s microbiome platform will propel the global launch of breakthrough products for livestock, companion animal and human health: MicroSintesis, a life science company focused on developing proprietary microbiome therapies today, at the Vet […]
DayTwo, the microbiome human discovery platform that offers a glycemic control solution for people with type 2 diabetes, announced $31 Million in Series B financing. DayTwo will use the funding to accelerate go-to-market initiatives in […]
Axial Biotherapeutics, a biotechnology company dedicated to building a unique class of gut-targeted therapeutics for neurodegenerative diseases and neurodevelopmental disorders, announced a direct investment of $10 million from Taiho Ventures, LLC to fund the discovery […]
DermBiont, a clinical stage therapeutics company dedicated to the discovery and development of live bacterial products for the treatment of skin diseases has closed an $8M Series A. The funding round was led by Zola […]
Intralytix, Inc., announced today that is has entered into a joint collaboration agreement with the Eliava Foundation and Ferring Pharmaceuticals to develop and commercialize new and innovative bacteriophage-based drugs in the field of Reproductive Medicine […]
Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage company applying synthetic biology to beneficial microbes to develop novel, living medicines and Ginkgo Bioworks, the organism company, today announced a platform collaboration to accelerate expansion and development of […]
BiomX Ltd., a microbiome company developing both natural and engineered phage therapies, today announced it has licensed a new set of bacterial targets from JSR Corporation, for the development and commercialization of phage therapies for […]
Whole Biome, an evidence-based microbiome company, today announced that it has secured $35 million in Series B financing. The round was led by existing investor Sequoia Capital with repeat participation from True Ventures, Khosla Ventures, […]
Crown Laboratories, Inc. (“Crown”), a leading, fully integrated skin care company, announced it has acquired Xycrobe Therapeutics, Inc. (“Xycrobe”). Xycrobe’s technology focuses on utilizing the ubiquitous nature of skin microbes by turning them into vehicles […]
Synlogic, Inc., (Nasdaq: SYBX) a clinical stage company applying synthetic biology to beneficial microbes to develop novel, living medicines, today announced a new clinical collaboration with Roche (SIX:RO, ROG), to explore Synlogic’s Synthetic Biotic™ medicine, SYNB1891, […]